Coumarins as modulators of autophagy and PI3K/mTOR signaling: implications for next-generation cancer therapies

Yasser Fakri Mustafa1

  • 1Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq.

Biomedical Journal
|June 15, 2026
PubMed
Abstract

Insights

Coumarin derivatives show promise in cancer therapy by modulating autophagy and PI3K/mTOR signaling. These compounds can induce or inhibit autophagy, impacting cancer cell survival and treatment resistance, paving the way for new therapeutic strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Aberrant autophagy and PI3K/mTOR signaling are key drivers of cancer progression and therapeutic resistance.
  • Coumarins, a diverse class of compounds, are emerging as regulators of these critical cancer pathways.

Purpose of the Study:

  • To review evidence on coumarin derivatives' regulation of autophagy and PI3K/mTOR signaling in cancer.
  • To explore their mechanistic basis, therapeutic potential, and clinical translation.

Main Methods:

  • Systematic review of preclinical studies from major scientific databases.
  • Analysis focused on coumarins, autophagy, PI3K/mTOR, and cancer models.
  • Evaluation of mechanistic data, pharmacokinetics, safety, and combination therapies.

Main Results:

  • Coumarins exhibit context-dependent modulation of autophagy, influencing cancer cell fate.
  • These effects are often mediated by direct or indirect regulation of PI3K/mTOR signaling.
  • Many coumarins display multitarget activity, favorable safety profiles, and potential in combination therapies.

Conclusions:

  • Coumarins are versatile scaffolds for modulating cancer-related autophagy and PI3K/mTOR signaling.
  • Further research into mechanisms, pharmacokinetics, and patient stratification is needed for clinical application.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...